3 Result(s)

Article

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

The SHIVA trial is a multicentric randomised proof-of-concept phase II trial comparing molecularly targeted therapy based on tumour molecular profiling vs conventional therapy in patients with any type of refract...

C Le Tourneau, X Paoletti, N Servant, I Bièche, D Gentien… in British Journal of Cancer (2014)

Article

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

The TP53 pathway, in which TP53 and its negative regulator MDM2 are the central elements, has an important role in carcinogenesis, particularly in BRCA1- and BRCA2-mediated carcinogenesis. A single nucleotide pol...

O M Sinilnikova, A C Antoniou, J Simard, S Healey, M Léoné… in British Journal of Cancer (2009)

Article

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

E Rouleau, F Spyratos, B Dieumegard, J M Guinebretière… in British Journal of Cancer (2008)